Literature DB >> 27217711

von Willebrand factor antigen as a therapeutic target of portal hypertension in cirrhosis.

Georgios N Kalambokis1, Gerasimos Baltayiannis1, Dimitrios Christodoulou1.   

Abstract

Increased thrombotic potential within the liver sinusoids due to local endothelial production of von Willebrand factor antigen macromolecules could represent an additional therapeutic target of portal hypertension in patients with cirrhosis. In this case, anti-inflammatory and antithrombotic drugs could modulate portal pressure by preventing the formation of intrahepatic platelet-induced microthrombi.

Entities:  

Keywords:  Endothelial dysfunction; Portal hypertension; Treatment; von Willebrand factor antigen

Mesh：

Substances：

Year:  2016        PMID： 27217711      PMCID： PMC4870086          DOI： 10.3748/wjg.v22.i19.4786

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  26 in total

1.  von Willebrand factor as a novel noninvasive predictor of portal hypertension and esophageal varices in hepatitis B patients with cirrhosis.

Authors:  Hao Wu; Shiping Yan; Guangchuan Wang; Shaobo Cui; Chunqing Zhang; Qiang Zhu
Journal:  Scand J Gastroenterol       Date:  2015-04-16       Impact factor: 2.423

2.  Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis.

Authors:  Pablo Bellot; Juan Carlos García-Pagán; Rubén Francés; Juan G Abraldes; Miguel Navasa; Miguel Pérez-Mateo; José Such; Jaime Bosch
Journal:  Hepatology       Date:  2010-10-26       Impact factor: 17.425

Review 3.  Pathological bacterial translocation in liver cirrhosis.

Authors:  Reiner Wiest; Melissa Lawson; Markus Geuking
Journal:  J Hepatol       Date:  2013-08-28       Impact factor: 25.083

Review 4.  Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress.

Authors:  Balasubramaniyan Vairappan
Journal:  World J Hepatol       Date:  2015-03-27

Review 5.  Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis.

Authors:  Dmitry Victorovich Garbuzenko
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

6.  Regulation of murine protein C gene expression in vivo: effects of tumor necrosis factor-alpha, interleukin-1, and transforming growth factor-beta.

Authors:  K Yamamoto; T Shimokawa; T Kojima; D J Loskutoff; H Saito
Journal:  Thromb Haemost       Date:  1999-10       Impact factor: 5.249

7.  Tissue distribution of factor VIII gene expression in vivo--a closer look.

Authors:  M J Hollestelle; T Thinnes; K Crain; A Stiko; J K Kruijt; T J van Berkel; D J Loskutoff; J A van Mourik
Journal:  Thromb Haemost       Date:  2001-09       Impact factor: 5.249

Review 8.  New determinants of prognosis in bacterial infections in cirrhosis.

Authors:  Juan Acevedo; Javier Fernández
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 9.  Vascular endothelial dysfunction in cirrhosis.

Authors:  Yasuko Iwakiri; Roberto J Groszmann
Journal:  J Hepatol       Date:  2007-03-05       Impact factor: 25.083

10.  Interleukin 1 or endotoxin increases the release of von Willebrand factor from human endothelial cells.

Authors:  A E Schorer; C F Moldow; M E Rick
Journal:  Br J Haematol       Date:  1987-10       Impact factor: 6.998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.